6.34
-0.35 (-5.23%)
| Penutupan Terdahulu | 6.69 |
| Buka | 6.65 |
| Jumlah Dagangan | 507,130 |
| Purata Dagangan (3B) | 738,103 |
| Modal Pasaran | 296,146,464 |
| Harga / Jualan (P/S) | 1.32 |
| Harga / Buku (P/B) | 0.680 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Keuntungan | -35.28% |
| Margin Operasi (TTM) | -86.92% |
| EPS Cair (TTM) | -1.24 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -5.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.51% |
| Nisbah Semasa (MRQ) | 8.29 |
| Aliran Tunai Operasi (OCF TTM) | -28.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.46 M |
| Pulangan Atas Aset (ROA TTM) | -9.38% |
| Pulangan Atas Ekuiti (ROE TTM) | -14.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | Quanterix Corporation | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.83 |
|
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.66% |
| % Dimiliki oleh Institusi | 89.70% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Trium Capital Llp | 31 Dec 2025 | 817,451 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection |
| 21 Jan 2026 | Pengumuman | Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling |
| 16 Jan 2026 | Pengumuman | Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08 Jan 2026 | Pengumuman | Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |